Core Insights - 60 Degrees Pharmaceuticals has entered a sponsored research agreement with Tulane University to study the effectiveness of tafenoquine against Borrelia and Bartonella, which are significant pathogens in Lyme disease [1][3] - The study aims to address the unmet need for effective treatments for tick-borne diseases, particularly in patients with co-infections [3] Company Overview - 60 Degrees Pharmaceuticals focuses on developing new medicines for infectious diseases and achieved FDA approval for its lead product, ARAKODA (tafenoquine), for malaria prevention in 2018 [16] - The company collaborates with research organizations in the U.S., Australia, and Singapore, and has received support from the U.S. Department of Defense and private investors [16] Product Information - Tafenoquine is an 8-aminoquinoline antimalarial drug approved for malaria prophylaxis, with a long terminal half-life of approximately 16 days, allowing for less frequent dosing [5] - ARAKODA is not approved for the treatment or prevention of babesiosis, Borrelia, or Bartonella [4][5] Research Significance - The study at Tulane University will further investigate tafenoquine's potential in treating co-infections in patients suffering from babesiosis [3] - Understanding the interactions between these pathogens is crucial for developing effective treatments for Lyme disease and related conditions [2][3]

Core Insights - Knight Therapeutics Inc. has successfully completed the acquisition of the Paladin business for approximately $107 million in cash, which includes $22.3 million allocated for inventory [1][2] - The acquisition is expected to enhance Knight's growth trajectory in Canada, positioning it as a significant revenue contributor over the next two years [3] Financial Details - The closing payment of $107 million was reduced by a holdback amount of $15.4 million, with $10 million potentially being released under specific conditions and $5.4 million earmarked for settling certain liabilities [2] - Future contingent payments of up to $15 million may be made upon achieving specific sales milestones [2] Strategic Outlook - The integration of Knight's Canadian business with the Paladin and Sumitomo portfolios is anticipated to create critical mass and change the growth trajectory of the company [3] - Knight remains well-positioned to continue acquiring, in-licensing, developing, and commercializing pharmaceutical products in Latin America and Canada following the closure of both Paladin and Sumitomo acquisitions [3] Company Overview - Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America [4] - The company's Latin American subsidiaries operate under the names United Medical, Biotoscana Farma, and Laboratorio LKM [4]

Core Viewpoint - Knight Therapeutics Inc. has secured a revolving credit facility with National Bank of Canada to support its growth strategy and acquisition plans, particularly for the Paladin acquisition [1][2][4]. Group 1: Credit Facility Details - The initial borrowing limit of the credit facility is up to US$50 million, with plans to increase it to at least US$100 million plus an accordion of US$50 million within the next six months [2][5]. - The credit facility can be drawn in either USD or CAD at the SOFR or CORRA rate plus a margin of 1.25% to 2.75%, depending on the company's debt leverage [3]. - The facility has an initial term of three years, extendable annually, and includes customary financial and non-financial covenants [2][3]. Group 2: Company Strategy and Leadership Statements - The credit facility is intended to enhance the company's operational strength and balance sheet, enabling it to pursue acquisition opportunities and support business growth in Latin America and Canada [4][5]. - The CFO of Knight Therapeutics expressed that the facility will optimize the capital structure and provide necessary funding for growth [5].

Core Insights - Knight Therapeutics Inc. has entered into exclusive license and supply agreements with Sumitomo Pharma America Inc. to commercialize MYFEMBREE, ORGOVYX, and vibegron in Canada, along with an asset purchase agreement for certain mature products [1][2] - The Products generated C$11.2 million in revenue for the year ended March 2025, indicating a potential growth opportunity for Knight in the Canadian market [1] - The transaction includes an upfront payment of C$25.4 million, with potential future payments of up to C$15.75 million based on sales milestones, and an estimated C$7 million for inventory [2] Company Overview - Knight Therapeutics Inc. is a specialty pharmaceutical company focused on acquiring and commercializing pharmaceutical products for Canada and Latin America, with shares trading on TSX under the symbol GUD [9] - Sumitomo Pharma Co., Ltd. is a global pharmaceutical company based in Japan, focusing on oncology, urology, women's health, and other therapeutic areas [11] Product Details - MYFEMBREE is the first oral prescription treatment for managing heavy menstrual bleeding associated with uterine fibroids and moderate to severe pain associated with endometriosis, generating approximately C$2.9 million in sales in Canada in 2024 [5] - ORGOVYX is the first oral GnRH receptor antagonist approved in Canada for advanced prostate cancer, with sales of approximately C$1.2 million in 2024 [6] - Vibegron is indicated for the treatment of overactive bladder in the U.S. and works by targeting β3 adrenergic receptors to alleviate symptoms [8]

Core Points - 60 Degrees Pharmaceuticals, Inc. has introduced a new 8-count bottle format for ARAKODA® (tafenoquine), aimed at patients traveling to malaria-endemic areas for shorter durations [1][2] - The new packaging option enhances accessibility for healthcare professionals prescribing ARAKODA for malaria prevention during trips of one week or less [2] - ARAKODA is the only weekly prophylactic therapy that protects against all stages of malaria for individuals aged 18 and older [3][4] Product Information - Tafenoquine, the active ingredient in ARAKODA, was discovered by the Walter Reed Army Institute of Research and received FDA approval for malaria prophylaxis in 2018 [4] - ARAKODA is available as a prescription-only medication and is distributed through pharmaceutical wholesaler networks in the U.S. and Australia [4] - The dosing regimen includes a loading phase of 2 x 100 mg tablets once daily for three days before travel, followed by 2 x 100 mg tablets weekly during travel, and 2 x 100 mg in the week following travel [4] Safety Information - ARAKODA is contraindicated in patients with G6PD deficiency, a history of psychotic disorders, or known hypersensitivity to tafenoquine [6][9] - The drug may cause serious adverse reactions, including hemolytic anemia and methemoglobinemia, necessitating monitoring and appropriate therapy [8][11] - Common adverse reactions reported include headache, dizziness, and gastrointestinal issues, with a notable incidence of psychiatric effects in susceptible individuals [11] Company Overview - 60 Degrees Pharmaceuticals, Inc. specializes in developing and marketing new medicines for infectious diseases, with a focus on malaria prevention [14] - The company was founded in 2010 and has received support from the U.S. Department of Defense and private investors [14] - The headquarters is located in Washington D.C., with a majority-owned subsidiary in Australia [14]

Core Insights - 60 Degrees Pharmaceuticals, Inc. announced results from an insurance claims analysis indicating a significant discrepancy between the number of Americans seeking reimbursement for babesiosis-related medical costs and CDC estimates of actual cases [1][2][10] - The company is investigating the true burden of babesiosis, particularly its association with chronic fatigue, through ongoing clinical trials and studies [6][8][10] Claims Analysis - Approximately 25,000 Americans seek reimbursement for babesiosis-related medical costs annually, while CDC estimates only 2,000 cases in 2020 [2][10] - Claims data revealed that about 31% of babesiosis cases persist longer than 30 days, with nearly half of these cases associated with chronic fatigue lasting over six months [4][10] Chronic Fatigue Insights - Babesia infections can last at least 12 months in 14% of patients, with potential relapses occurring up to 27 months later [3] - Over three years, more than 12 million U.S. adults experienced chronic fatigue lasting more than six months, yet current guidelines do not mandate babesiosis as a differential diagnosis for such fatigue [5][10] Clinical Development - The company is conducting clinical trials to evaluate the safety and efficacy of tafenoquine in treating babesiosis, with data expected in the first half of 2026 [8][10] - A new drug application (NDA) for babesiosis is anticipated to be submitted to the FDA in 2026 [8][10] Product Information - Tafenoquine, marketed as ARAKODA, was approved for malaria prophylaxis in 2018 and is available as a prescription-only medication [9][10] - The drug has a long terminal half-life of approximately 16 days, allowing for less frequent dosing [9]

MONTREAL, May 13, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20, 2025 at 3:35 pm ET at the InterContinental New York Barclay hotel in New York City. About Knight Therapeutics Inc. CONTACT INFORMATION: Investor Contact: Knight ...

Financial Results - Revenues for Q1-25 were $88,076, an increase of $1,472 or 2% compared to Q1-24, driven by growth in key promoted products, partially offset by declines in mature products and currency depreciation in select LATAM countries [7][13] - Gross margin decreased to $34,866 or 40% of revenues from $41,699 or 48% in the same period last year, primarily due to hyperinflation accounting in Argentina [7][19] - Operating loss was $5,537 compared to an operating income of $2,660 in Q1-24 [11][25] - Net income was $2,185, a significant improvement from a net loss of $4,546 in the prior year [25] - Adjusted revenues were $87,979, reflecting a 3% increase, and $6,631 or 8% on a constant currency basis [7][13] Corporate Developments - The company entered into an asset purchase agreement to acquire the Paladin business for $100,000, with an additional $20,000 for inventory, and potential future payments of up to $15,000 based on sales milestones [7][36] - A working capital line of credit of USD 40,000 was obtained from Citibank, with USD 35,000 withdrawn [6][37] - The company in-licensed Onicit IV for distribution in Mexico, Brazil, and select LATAM countries, and submitted Tavalisse for ANMAT approval in Argentina [8][33][35] Shareholder Updates - Shareholders re-elected members to the Board of Directors, including Jonathan Ross Goodman and Samira Sakhia [9] Financial Outlook - The company reaffirmed its financial guidance for 2025, expecting revenues between $390 million to $405 million and adjusted EBITDA to be approximately 13% of revenues [38]

Core Points - Knight Therapeutics Inc. held its Annual General Meeting of Shareholders virtually in Montreal, Quebec, where key voting results were announced [1] Group 1: Election of Directors - All director nominees listed in the Management Information Circular dated April 4, 2025, were elected as Directors of the Corporation [2] - Jonathan Ross Goodman received 59,911,976 votes (96.70% for) and 2,041,772 votes (3.30% against) [2] - James C. Gale received 61,421,942 votes (99.14% for) and 531,806 votes (0.86% against) [2] - Samira Sakhia received 61,868,351 votes (99.86% for) and 85,397 votes (0.14% against) [2] - Robert N. Lande received 61,742,628 votes (99.66% for) and 211,120 votes (0.34% against) [2] - Michael J. Tremblay received 59,558,152 votes (96.13% for) and 2,395,596 votes (3.87% against) [2] - Nicolás Sujoy received 61,749,390 votes (99.67% for) and 204,358 votes (0.33% against) [2] - Janice Murray received 61,750,229 votes (99.67% for) and 203,519 votes (0.33% against) [2] Group 2: Appointment of External Auditors - Ernst & Young LLP was appointed as external auditors for the next year with 62,087,609 votes (99.60% for) and 248,512 votes (0.40% withheld) [3] Group 3: Employee and Director Share Purchase Plan - The resolution to renew unallocated rights under the Corporation's employee and director share purchase plan was approved with 54,409,705 votes (87.82% for) and 7,544,043 votes (12.18% against) [4] Group 4: Company Overview - Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, focusing on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America [5] - The company's Latin American subsidiaries operate under United Medical, Biotoscana Farma, and Laboratorio LKM [5] - Knight Therapeutics Inc.'s shares are traded on TSX under the symbol GUD [5]

In May 2022, Knight and Helsinn Healthcare SA ("Helsinn") had entered into an exclusive license, distribution and supply agreement for oral/IV AKYNZEO (netupitant/palonosetron - fosnetupitant /palonosetron) in Canada, Brazil, Argentina, Uruguay and Paraguay, and ALOXI oral/IV (palonosetron) in Canada. In January 2025, Knight and Helsinn announced that they expanded their existing relationship and entered into an exclusive license, distribution and supply agreement for ONICIT IV (palonosetron) in Mexico, Bra ...